Chimeric Therapeutics Boosted by R&D Tax Incentive

Chimeric Therapeutics Ltd. (AU:CHM) has released an update.

Chimeric Therapeutics, a leader in cell therapy research, has secured a $4.17 million refund through the Australian Government’s R&D Tax Incentive, highlighting its innovative work in cancer treatment. The company is advancing a robust portfolio of pioneering CAR T and NK cell therapies across various oncology fields, with ongoing clinical trials demonstrating promising results. This financial boost underscores Chimeric’s commitment to developing cutting-edge therapies to combat cancer.

For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.